Oral diseases · 2025
Reporting Quality of Adverse Events in Temporomandibular Disorders Treatment: A Systematic Review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Chen, Li Yi-Hang, Zheng Yun-Hao, Li Wei, Wo Po-Kam, Park Ji Woon, Wang Jun, Xiong Xin
Аннотация
OBJECTIVE: To evaluate the quality of adverse event (AE) reporting and identify factors associated with reporting quality in randomized controlled trials (RCTs) of temporomandibular disorders (TMDs) treatment.
METHODS: We searched MEDLINE, Cochrane Library (CENTRAL), and EMBASE for RCTs on TMD treatment. Trial characteristics and AE data were extracted, with specific AEs classified using System Organ Class (SOC) terminology. We assessed the reporting quality with the 16-item CONSORT Harms 2022 checklist. Factors influencing reporting quality were analyzed using multiple linear regression and an artificial neural network (ANN) with SHapley Additive exPlanations (SHAP) interpretation.
RESULTS: Of 79 RCTs analyzed, neurological symptoms (e.g., headache, dizziness) were the primary AEs. Only three checklist items were reported in over 50% of studies. The median reporting score percentage was 18.8% (IQR 26.7%). No significant differences in score percentages were observed across treatment modalities (p = 0.565). We finally screened out five key factors linked to higher reporting quality, including non-profit funding, combined efficacy-safety endpoints, absence of international collaboration, European country location, and registration status.
CONCLUSIONS: AE reporting quality in TMDs treatment RCTs remains suboptimal. Adherence to the most current CONSORT Harms guidelines is recommended to improve transparency and consistency in harms reporting.
METHODS: We searched MEDLINE, Cochrane Library (CENTRAL), and EMBASE for RCTs on TMD treatment. Trial characteristics and AE data were extracted, with specific AEs classified using System Organ Class (SOC) terminology. We assessed the reporting quality with the 16-item CONSORT Harms 2022 checklist. Factors influencing reporting quality were analyzed using multiple linear regression and an artificial neural network (ANN) with SHapley Additive exPlanations (SHAP) interpretation.
RESULTS: Of 79 RCTs analyzed, neurological symptoms (e.g., headache, dizziness) were the primary AEs. Only three checklist items were reported in over 50% of studies. The median reporting score percentage was 18.8% (IQR 26.7%). No significant differences in score percentages were observed across treatment modalities (p = 0.565). We finally screened out five key factors linked to higher reporting quality, including non-profit funding, combined efficacy-safety endpoints, absence of international collaboration, European country location, and registration status.
CONCLUSIONS: AE reporting quality in TMDs treatment RCTs remains suboptimal. Adherence to the most current CONSORT Harms guidelines is recommended to improve transparency and consistency in harms reporting.